A randomized, open-label, crossover study to evaluate ICS/LABA treatment versus LAMA/LABA treatment in COPD with eosinophilic inflammation

A randomized, open-label, crossover study to evaluate ICS/LABA treatment versus LAMA/LABA treatment in COPD with eosinophilic inflammation - COPD and eosinophilic inflammation.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024905

Enrollment

Registered

2016-11-21

Start date

2016-11-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

Treatment with ICS/LABA for 4 weeks, then treatment with LAMA/LABA for 4 weeks. Treatment with LAMA/LABA for 4 weeks, then tteatment with ICS/LABA for 4 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Severity of airflow limitation as GOLD 2-4; have a smoking history of at least 10 pack-years; and FENO level of at least 25 ppb.

Exclusion criteria

Exclusion criteria: Asthma overlap (ACOS); history of lung resection; using inhaled or oral corticosteroid; receiving anti-IgE therapy; and exacerbation of COPD in the 4 weeks.

Design outcomes

Primary

Measure	Time frame
FEV1 after 4 weeks of treatment.	—

Secondary

Measure	Time frame
Dyspnoea, symptoms, FENO level, and blood eosinophils after 4 weeks of treatment. Adverse events and exacerbation.	—

Countries

Japan

Contacts

Public ContactSeiichi Kobayashi

Japanese Red Cross Ishinomaki Hospital Department of Respiratory Medicine

skoba-thk@umin.ac.jp0225-21-7220

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026